Proteomics of human neurodegenerative diseases

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 10, 2008, Pages 923-932

  Zhang, Jing ^a   Keene, C Dirk ^a   Pan, Catherine ^a   Montine, Kathleen S ^a   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer disease; Cerebrospinal fluid; Mass spectrometry; Neurodegeneration; Parkinson disease; Proteomics

Indexed keywords

ALPHA ENOLASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIOXIDANT; CREATINE KINASE; GLUTAMATE AMMONIA LIGASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PEROXIREDOXIN 2; SYNAPTOTAGMIN I; TAU PROTEIN; TRIOSEPHOSPHATE ISOMERASE; NERVE PROTEIN; PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; BIOINFORMATICS; BRAIN CORTEX; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; DOWN SYNDROME; FRONTAL CORTEX; GEL ELECTROPHORESIS; HUMAN; HUNTINGTON CHOREA; LASER CAPTURE MICRODISSECTION; LEWY BODY; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PAIRED HELICAL FILAMENT; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; BRAIN; BRAIN LEVEL; CEREBROSPINAL FLUID; CHEMISTRY; GENETICS; METHODOLOGY; PATHOLOGY;

BRAIN; BRAIN CHEMISTRY; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PROTEINS; PROTEOMICS;

EID: 54449097885     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318187a832     Document Type: Review

References (99)

1. Ideker T, Thorsson V, Ranish JA, et al. Integrated genomic and pro-teomic analyses of a systematically perturbed metabolic network. Science 2001;292:929-934
2. Johnson MD, Yu LR, Conrads TP, et al. Proteome analysis of DNA damage-induced neuronal death using high throughput mass spectrometry. J Biol Chem 2004;279:26685-26697
3. Griffin TJ, Gygi SP, Ideker T, et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002;1:323-333
4. Tsuang DW, Bird TD. Genetics of dementia. Med Clin North Am 2002; 86:591-614
5. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J Am Soc Mass Spectrom 1994;5:976-989
6. Fenyo D, Beavis RC. A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. Anal Chem 2003;75:768-774
7. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17:994-999
8. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3:1154-1169
9. Haqqani AS, Kelly JF, Stanimirovic DB. Quantitative protein profiling by mass spectrometry using label-free proteomics. In: Starkey M, Elaswarapu R, eds. Genomics Protocols, vol.439. Totowa, NJ: Humana Press, 2008;241-256
10. Dijkstra M, Vonk RJ, Jansen RC. SELDI-TOF mass spectra: A view on sources of variation. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:12-23
11. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007;53:852-858
12. Cornett DS, Reyzer ML, Chaurand P, et al. MALDI imaging mass spectrometry: Molecular snapshots of biochemical systems. Nat Methods 2007;4:828-833
13. Tanner S, Shu H, Frank A, et al. InsPecT: Identification of posttranslationally modified peptides from tandem mass spectra. Anal Chem 2005; 77:4626-4639
14. Hansen BT, Davey SW, Ham AJ, et al. P-Mod: An algorithm and software to map modifications to peptide sequences using tandem MS data. J Proteome Res 2005;4:358-368
15. Schonberger SJ, Edgar PF, Kydd R, et al. Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics 2001;1:1519-1528
16. Shiozaki A, Tsuji T, Kohno R, et al. Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation. J Alzheimers Dis 2004;6:257-268
17. Kim SH, Vlkolinsky R, Cairns N, et al. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 2000;57: 1810-1816
18. Krapfenbauer K, Engidawork E, Cairns N, et al. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 2003; 967:152-160
19. Liao L, Cheng D, Wang J, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 2004;279:37061-37068
20. Wang Q, Woltjer RL, Cimino PJ, et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 2005;19:869-871
21. Li Y, Nowotny P, Holmans P, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A 2004;101:15688-15693
22. Lin PI, Martin ER, Bronson PG, et al. Exploring the association of glyceraldehyde-3-phosphate dehydrogenase gene and Alzheimer disease. Neurology 2006;67:64-68
23. Olah J, Tokesi N, Vincze O, et al. Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Lett 2006;580:5807-5814
24. Cumming RC, Schubert D. Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. FASEB J 2005;19: 2060-2062
25. Sultana R, Boyd-Kimball D, Cai J, et al. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 2007;11: 153-164
26. Wakabayashi K, Tanji K, Mori F, et al. The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007;27:494-506
27. Leverenz JB, Umar I, Wang Q, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol (Zurich, Switzerland) 2007;17:139-145
28. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884
29. Trojanowski JQ, Lee VM. Brain degeneration linked to Bfatal attractions[ of proteins in Alzheimer's disease and related disorders. J Alzheimers Dis 2001;3:117-119
30. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophy Res Comm 1984;120:885-890
31. Lee VM, Balin BJ, Otvos L Jr, et al. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251:675-678
32. Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Ann Rev Pathol 2006;1:151-170
33. Woltjer RL, Cimino PJ, Boutte AM, et al. Proteomic determination of widespread detergent-insolubility including AA but not tau early in the pathogenesis of Alzheimer's disease. FASEB J 2005;19:1923-1925
34. Yang W, Woltjer RL, Sokal I, et al. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonismdementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. Am J Pathol 2007;171:993-1002
35. Winton MJ, Joyce S, Zhukareva V, et al. Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. Acta Neuropathol (Berl) 2006;111:401-12
36. Sebeo J, Hof PR, Perl DP. Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol 2004;107:497-503
37. Forman MS, Schmidt ML, Kasturi S, et al. Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol 2002;160:1725-1731
38. Yamazaki M, Arai Y, Baba M, et al. Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2000;59:585-591
39. Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002;33:562-571
40. Castegna A, Aksenov M, Thongboonkerd V, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002;82:1524-1532
41. Choi J, Levey AI, Weintraub ST, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004;279:13256-13264
42. Butterfield DA, Sultana R. Identification of 3-Nitrotyrosine-modified brain proteins by redox proteomics. Methods Enzymol 2008;440: 295-308
43. Sultana R, Reed T, Perluigi M, et al. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: A regional study. J Cell Mol Med 2007;11:839-851 (Pubitemid 47313301)
44. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007;1148:243-248
45. Cripps D, Thomas SN, Jeng Y, et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 2006;281:10825-10838
46. Boutte AM, Woltjer RL, Zimmerman LJ, et al. Selectively increased oxidative modifications mapped to detergent-insoluble forms of AA and beta-III tubulin in Alzheimer's disease. FASEB J 2006;20:1473-1483
47. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-819
48. Basso M, Giraudo S, Corpillo D, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004;4:3943-3952
49. Shi M, Jin J, Wang Y, et al. Mortalin: A protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol 2008;67: 117-124
50. Jin J, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: Relevance to Parkinson disease. Mol Cell Proteomics 2006;5:1193-1204
51. Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: A housekeeper, guardian and killer. Exp Gerontol 2007;42:263-274
52. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-1494
53. Blennow K. CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005; 5:661-672
54. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92
55. D'Ascenzo M, Relkin NR, Lee KH. Alzheimer's disease cerebrospinal fluid biomarker discovery: A proteomics approach. Curr Opin Mol Ther 2005;7:557-564
56. Galasko D. Biomarkers for Alzheimer's diseaseVclinical needs and application. J Alzheimers Dis 2005;8:339-346
57. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of {beta}-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345
58. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006;9: 293-348
59. Davidsson P, Westman-Brinkmalm A, Nilsson CL, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002;13:611-615
60. Puchades M, Hansson SF, Nilsson CL, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-146
61. Zhang J, Goodlett DR, Peskind ER, et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005;26:207-227
62. Zhang J, Goodlett DR, Quinn JF, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 2005;7:125-133
63. Pan S, Wang Y, Quinn JF, et al. Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res 2006;5:2769-2779
64. Finehout EJ, Franck Z, Choe LH, et al. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007;61:120-129
65. Hu Y, Malone JP, Fagan AM, et al. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005;4:2000-2009
66. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66:1218-1222
67. Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn 2006;6:387-398
68. McComb JG. Recent research into the nature of cerebrospinal fluid formation and absorption. J Neurosurg 1983;59:369-383
69. Han CY, Backous DD. Basic principles of cerebrospinal fluid metabolism and intracranial pressure homeostasis. Otolaryngol Clin North Am 2005;38:569-576
70. Bergsneider M. Evolving concepts of cerebrospinal fluid physiology. Neurosurg Clin N Am 2001;12:631-638, vii
71. Huhmer AF, Biringer RG, Amato H, et al. Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers 2006;22:3-26
72. Nilsson C, Stahlberg F, Thomsen C, et al. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol 1992;262:R20-R24
73. Preston JE. Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 2001;52:31-37
74. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993;33:129-133 (Pubitemid 23100537)
75. Blennow K, Fredman P, Wallin A, et al. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 1993;33:126-128
76. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. Eur Neurol 1993;33:134-142
77. Osman I, Gaillard O, Meillet D, et al. A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases. Eur J Clin Chem Clin Biochem 1995;33:53-58
78. Carrette O, Burkhard PR, Hughes S, et al. Truncated cystatin C in cerebrospinal fluid: Technical [corrected] artefact or biological process? Proteomics 2005;5:3060-3065
79. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 2006;6:6326-6353
80. Hardt M, Thomas LR, Dixon SE, et al. Toward defining the human parotid gland salivary proteome and peptidome: Identification and characterization using 2D SDS-PAGE, ultrafiltration, HPLC, and mass spectrometry. Biochemistry 2005;44:2885-2899
81. Davidsson P, Nilsson CL. Peptide mapping of proteins in cerebrospinal fluid utilizing a rapid preparative two-dimensional electrophoretic procedure and matrix-assisted laser desorption/ionization mass spectrometry. Biochim Biophys Acta 1999;1473:391-399
82. Raymackers J, Daniels A, De Brabandere V, et al. Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization-mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. Electro-phoresis 2000;21:2266-2283
83. Sickmann A, Dormeyer W, Wortelkamp S, et al. Towards a high resolution separation of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2002;771:167-196
84. Finehout EJ, Franck Z, Lee KH. Towards two-dimensional electro-phoresis mapping of the cerebrospinal fluid proteome from a single individual. Electrophoresis 2004;25:2564-2575
85. Maccarrone G, Milfay D, Birg I, et al. Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 2004;25:2402-2412
86. Ramstrom M, Ivonin I, Johansson A, et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spec-trometry. Proteomics 2004;4:4010-4018 (Pubitemid 39662757)
87. Wenner BR, Lovell MA, Lynn BC. Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 2004;3: 97-103
88. Xu J, Chen J, Peskind E, et al. Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol 2006;73:29-98
89. Sanchez JC, Guillaume E, Lescuyer P, et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004;4:2229-2233
90. Irani DN, Anderson C, Gundry R, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006; 59:237-247
91. Mannes AJ, Martin BM, Yang HY, et al. Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 2003;102:251-256
92. Simonsen AH, McGuire J, Podust VN, et al. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 2007;24:434-440
93. Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007;64:366-370
94. Ranganathan S, Williams E, Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005;95:1461-1471
95. Ruetschi U, Zetterberg H, Podust VN, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Experimental Neurology 2005;196:273-281
96. Biroccio A, Del Boccio P, Panella M, et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. Proteomics 2006;6:2305-2313
97. Castano EM, Roher AE, Esh CL, et al. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006;28:155-63
98. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526-529
99. Pan S, Rush J, Peskind ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-offlight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 2008;7:720-730